Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Higher doses of naloxone are needed in the synthetic opiod era.

Moss RB, Carlo DJ.

Subst Abuse Treat Prev Policy. 2019 Feb 18;14(1):6. doi: 10.1186/s13011-019-0195-4.

2.

Human factors study of a newly approved prefilled syringe of epinephrine for the treatment of anaphylaxis.

Moss RB, Moll T, Daniels K, Carlo DJ.

Allergy Asthma Proc. 2018 Sep 1;39(5):389-393. doi: 10.2500/aap.2018.39.4154.

PMID:
30153890
3.

Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector.

Moss RB, Daniels K, Moll T, Carlo DJ.

Ann Allergy Asthma Immunol. 2018 May;120(5):540-541. doi: 10.1016/j.anai.2018.02.027. Epub 2018 Feb 27. No abstract available.

4.

Propofol hemisuccinate suppression of experimental autoimmune encephalomyelitis.

Vansant G, Trauger RJ, Cameron A, Vendemelio M, Kreitschitz S, Carlo AT, Banaszczyk MG, Carlo DJ, Hendler S, Ill CR.

Autoimmunity. 2007 May;40(3):180-6.

PMID:
17453716
6.

Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma.

Encinas JA, Janssen EM, Weiner DB, Calarota SA, Nieto D, Moll T, Carlo DJ, Moss RB.

J Allergy Clin Immunol. 2005 Dec;116(6):1343-9. Epub 2005 Oct 3.

PMID:
16337469
7.

Th1/Th2 cells in inflammatory disease states: therapeutic implications.

Moss RB, Moll T, El-Kalay M, Kohne C, Soo Hoo W, Encinas J, Carlo DJ.

Expert Opin Biol Ther. 2004 Dec;4(12):1887-96. Review.

PMID:
15571451
8.
9.

HIV-specific immunity during structured antiviral drug treatment interruption.

Moss RB, Brandt C, Giermakowska WK, Savary JR, Theofan G, Zanetti M, Carlo DJ, Wallace MR.

Vaccine. 2003 Mar 7;21(11-12):1066-71.

PMID:
12559781
10.

The strategy of immunologic control of HIV-1 with structured treatment interruptions (STIs).

Moss RB, Jensen FC, Carlo DJ, Wallace MR.

Curr Drug Targets Infect Disord. 2001 May;1(1):11-7. Review.

PMID:
12455230
11.

Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation.

Banaszczyk MG, Carlo AT, Millan V, Lindsey A, Moss R, Carlo DJ, Hendler SS.

Anesth Analg. 2002 Nov;95(5):1285-92, table of contents.

PMID:
12401612
12.

Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.

Yei S, Bartholomew RM, Pezzoli P, Gutierrez A, Gouveia E, Bassett D, Soo Hoo W, Carlo DJ.

Gene Ther. 2002 Oct;9(19):1302-11.

13.

Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model.

Moss RB, Savary JR, Diveley JP, Jensen F, Carlo DJ.

Immunology. 2002 Aug;106(4):549-53.

14.

Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.

Shawler DL, Bartholomew RM, Garrett MA, Trauger RJ, Dorigo O, Van Beveren C, Marchese A, Ferre F, Duffy C, Carlo DJ, Sherman LA, Gold DP, Sobol RE.

Clin Exp Immunol. 2002 Jul;129(1):99-106.

15.

Poly-L-lysine-based gene delivery systems. Synthesis, purification, and application.

Lollo CP, Banaszczyk MG, Mullen PM, Coffin CC, Wu D, Carlo AT, Bassett DL, Gouveia EK, Carlo DJ.

Methods Mol Med. 2002;69:1-13. No abstract available.

PMID:
11987770
16.

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.

Moss RB, Wallace MR, Steigbigel RT, Morrison SA, Giermakowska WK, Nardo CJ, Diveley JP, Carlo DJ.

Clin Exp Immunol. 2002 May;128(2):359-64.

17.

Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen.

Moss RB, Giermakowska WK, Wallace MR, Jensen FC, Maigetter RZ, Carlo DJ.

Clin Exp Immunol. 2001 May;124(2):248-54.

18.

Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis.

Morgan EE, Nardo CJ, Diveley JP, Kunin J, Bartholomew RM, Moss RB, Carlo DJ.

J Neurosci Res. 2001 May 1;64(3):298-301.

PMID:
11319774
20.

Enhancement of HIV Type 1 Antigen-Specific CD4+ T Cell Memory in Subjects with Chronic HIV Type 1 Infection Receiving an HIV Type 1 Immunogen.

Maino VC, Suni MA, Wormsley SB, Carlo DJ, Wallace MR, Moss RB.

AIDS Res Hum Retroviruses. 2000 Dec;16(18):2065-2066. No abstract available.

PMID:
11153091
21.

HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA.

Moss RB, Diveley J, Jensen FC, Gouveia E, Savary J, Carlo DJ.

J Interferon Cytokine Res. 2000 Dec;20(12):1131-7.

PMID:
11152580
22.

Strength of conjugate binding to plasmid DNA affects degradation rate and expression level in vivo.

Mullen PM, Lollo CP, Phan QC, Amini A, Banaszczyk MG, Fabrycki JM, Wu D, Carlo AT, Pezzoli P, Coffin CC, Carlo DJ.

Biochim Biophys Acta. 2000 Sep 1;1523(1):103-10.

PMID:
11099863
23.

Gene expression monitoring for gene discovery in models of peripheral and central nervous system differentiation, regeneration, and trauma.

Farlow DN, Vansant G, Cameron AA, Chang J, Khoh-Reiter S, Pham NL, Wu W, Sagara Y, Nicholls JG, Carlo DJ, Ill CR.

J Cell Biochem. 2000 Oct 20;80(2):171-80.

PMID:
11074584
24.

A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.

Churdboonchart V, Sakondhavat C, Kulpradist S, Na Ayudthya BI, Chandeying V, Rugpao S, Boonshuyar C, Sukeepaisarncharoen W, Sirawaraporn W, Carlo DJ, Moss R.

Clin Diagn Lab Immunol. 2000 Sep;7(5):728-33. Erratum in: Clin Diagn Lab Immunol 2001 Nov;8(6):1295.

26.
27.

Insights into HIV-specific immune function: implications for therapy and prevention in the new millennium.

Moss RB, Jensen FC, Carlo DJ.

Clin Immunol. 2000 May;95(2):79-84. Review. No abstract available.

PMID:
10779400
28.

Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen.

Maino VC, Suni MA, Wormsley SB, Carlo DJ, Wallace MR, Moss RB.

AIDS Res Hum Retroviruses. 2000 Apr 10;16(6):539-47. Erratum in: AIDS Res Hum Retroviruses 2000 Dec 10;16(18):2065-6.

PMID:
10777144
29.

CXCR4 and CCR5 expression on CD4+ T cells in vivo and HIV-1 antigen beta-chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE).

Moss RB, Giermakowska WK, Diveley JP, Savary JR, Wallace MR, Maigetter RZ, Jensen FC, Carlo DJ.

J Hum Virol. 2000 Jan-Feb;3(1):44-9.

PMID:
10774806
30.

Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen.

Moss RB, Giermakowska WK, Wallace MR, Savary JR, Jensen FC, Carlo DJ.

AIDS. 2000 Nov 10;14(16):2475-8.

PMID:
11101057
31.
32.

Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11986-91.

33.
34.

Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study.

Sobol RE, Shawler DL, Carson C, Van Beveren C, Mercola D, Fakhrai H, Garrett MA, Barone R, Goldfarb P, Bartholomew RM, Brostoff S, Carlo DJ, Royston I, Gold DP.

Clin Cancer Res. 1999 Sep;5(9):2359-65.

35.

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.

Moss RB, Wallace MR, Giermakowska WK, Webb E, Savary J, Chamberlin-Brandt C, Theofan G, Musil R, Richieri SP, Jensen FC, Carlo DJ.

J Infect Dis. 1999 Sep;180(3):641-8.

PMID:
10438350
36.
37.

Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.

Moss RB, Li L, Giermakowska WK, Lanza P, Turner JL, Wallace MR, Jensen FC, Richieri SP, Daigle AE, Theofan G, Carlo DJ.

J Hum Virol. 1998 Jan-Feb;1(2):77-81.

PMID:
10195235
38.

Stabilization of poly-L-lysine/DNA polyplexes for in vivo gene delivery to the liver.

Kwoh DY, Coffin CC, Lollo CP, Jovenal J, Banaszczyk MG, Mullen P, Phillips A, Amini A, Fabrycki J, Bartholomew RM, Brostoff SW, Carlo DJ.

Biochim Biophys Acta. 1999 Feb 16;1444(2):171-90.

PMID:
10023051
39.

T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides.

Moreland LW, Morgan EE, Adamson TC 3rd, Fronek Z, Calabrese LH, Cash JM, Markenson JA, Matsumoto AK, Bathon J, Matteson EL, Uramoto KM, Weyand CM, Koopman WJ, Heck LW, Strand V, Diveley JP, Carlo DJ, Nardo CJ, Richieri SP, Brostoff SW.

Arthritis Rheum. 1998 Nov;41(11):1919-29.

PMID:
9811045
40.

Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.

Churdboonchart V, Moss RB, Sirawaraporn W, Smutharaks B, Sutthent R, Jensen FC, Vacharak P, Grimes J, Theofan G, Carlo DJ.

AIDS. 1998 Aug 20;12(12):1521-7.

PMID:
9727574
41.

A primer on HIV type 1-specific immune function and REMUNE.

Moss RB, Giermakowska WK, Savary JR, Theofan G, Daigle AE, Richieri SP, Jensen FC, Carlo DJ.

AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S167-75. Review.

PMID:
9672235
42.

Non-viral gene delivery: vehicle and delivery characterization.

Lollo CP, Kwoh DY, Mockler TC, Ley PM, Guido MS, Coffin CC, Aleman R, Bartholomew RM, Carlo DJ.

Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S31-8.

PMID:
9607111
43.

Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography.

Richieri SP, Bartholomew R, Aloia RC, Savary J, Gore R, Holt J, Ferre F, Musil R, Tian HR, Trauger R, Lowry P, Jensen F, Carlo DJ, Maigetter RZ, Prior CP.

Vaccine. 1998 Jan-Feb;16(2-3):119-29.

PMID:
9607019
44.
45.

Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination.

Lanza P, Moss RB, Giermakowska W, Hancock RB, Richieri SP, Theofa G, Jensen FC, Salk PL, Carlo DJ.

Vaccine. 1998 Apr;16(7):727-31.

PMID:
9562693
46.

HIV-1-Specific Functional Immune Measurements as Markers of Disease Progression.

Moss RB, Richieri SP, Ferre F, Daigle AE, Trauger R, Theofan G, Giermakowska W, Lanza P, Brostoff S, Carlo DJ, Jensen FC.

J Biomed Sci. 1997 Jul-Aug;4(4):127-131.

PMID:
11725144
47.

Persistence of T-cell clones in psoriatic lesions.

Chang JC, Smith LR, Froning KJ, Kurland HH, Schwabe BJ, Blumeyer KK, Karasek MA, Wilkinson DI, Farber EM, Carlo DJ, Brostoff SW.

Arch Dermatol. 1997 Jun;133(6):703-8.

PMID:
9197823
48.

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide.

Gold DP, Smith RA, Golding AB, Morgan EE, Dafashy T, Nelson J, Smith L, Diveley J, Laxer JA, Richieri SP, Carlo DJ, Brostoff SW, Wilson DB.

J Neuroimmunol. 1997 Jun;76(1-2):29-38.

PMID:
9184630
49.

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations.

Wilson DB, Golding AB, Smith RA, Dafashy T, Nelson J, Smith L, Carlo DJ, Brostoff SW, Gold DP.

J Neuroimmunol. 1997 Jun;76(1-2):15-28.

PMID:
9184629
50.

Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection.

Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, Carlo DJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):343-50.

PMID:
9111476

Supplemental Content

Loading ...
Support Center